Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine for Walking Deficits in Post-Ischemic Stroke
NCT02271217Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of dalfampridine in ischemic stroke (3 arms), sponsored by Acorda Therapeutics. Primary endpoint: Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test at 12 weeks. Started Dec 2014; status: completed.
02
Drugs
dalfampridine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02271217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271217.